The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt.biotech. Regulatory News (IBT)

Share Price Information for Int.biotech. (IBT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 598.00
Bid: 596.00
Ask: 608.00
Change: -6.00 (-0.99%)
Spread: 12.00 (2.013%)
Open: 600.00
High: 600.00
Low: 598.00
Prev. Close: 604.00
IBT Live PriceLast checked at -
International Biotechnology is an Investment Trust

To achieve capital growth through investing in high growth, development stage biotechnology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Joint Lead Investment Managers

15 Mar 2021 12:43

RNS Number : 2914S
Intl. Biotechnology Trust PLC
15 March 2021
 

15 March 2021

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

 

APPOINTMENT OF JOINT LEAD INVESTMENT MANAGERS

 

The Board of International Biotechnology Trust (the "Company") and SV Health Investors announce that Carl Harald Janson has decided to step back from his role as Lead Investment Manager after seven successful years at the Company's helm.

Lead responsibility for portfolio management will transition to Ailsa Craig and Marek Poszepczynski and the Board has approved them as joint Lead Investment Managers. Following a handover period, Carl Harald will remain as a Senior Adviser to SV Health Investors. Kate Bingham will remain the Investment Manager of the Company's unquoted portfolio.

Ailsa and Marek have played key roles working alongside Carl Harald in the investment management team of the Company, and both have many years' experience in the biotechnology and healthcare industry and are scientifically trained. Ailsa has been an investment manager at SV Health Investors for 15 years, having previously worked as a healthcare research analyst. Marek joined SV Health Investors in 2014 as an investment manager, having previously worked for a decade in business development within the biotech industry, structuring and creating M&A transactions and IPOs as well as founding and managing several biotech companies.

Jim Horsburgh, Chairman, commented: "We thank Carl Harald for the pivotal role he has played over the past seven years leading International Biotechnology Trust to an all-time high in NAV terms in 2020, and wish him well for the future. Ailsa and Marek are extremely capable and long-standing core members of our investment team and we are confident that they will continue to deliver strong returns to shareholders."

 

 

For further information contact:

 

Broker - Numis

 

Nathan Brown +44 (0)20 7260 1426 / +44 (0)7795 964 870

 

Vicki Paine +44 (0)20 7260 1256 / +44 (0)78 8431 1486

 

 

Company Secretary - Link Company Matters

 

Claire Jackson +44 (0)7821 843993

 

 

LEI: 213800N1QUJ744P76D11

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLELFFFXLZBBL
Date   Source Headline
11th Apr 20225:32 pmRNSTransaction in Own Shares
11th Apr 202210:50 amPRNNet Asset Value(s)
8th Apr 202211:13 amPRNNet Asset Value(s)
7th Apr 202211:15 amPRNNet Asset Value(s)
6th Apr 20225:07 pmRNSTransaction in Own Shares
6th Apr 202210:59 amPRNNet Asset Value(s)
5th Apr 202211:11 amPRNNet Asset Value(s)
4th Apr 20225:37 pmRNSTransaction in Own Shares
4th Apr 202211:08 amPRNNet Asset Value(s)
4th Apr 202211:06 amPRNNet Asset Value(s)
1st Apr 20225:20 pmRNSTransaction in Own Shares
1st Apr 202212:46 pmRNSTotal Voting Rights
1st Apr 202212:40 pmRNSDirector/PDMR Shareholding
1st Apr 202211:09 amPRNNet Asset Value(s)
1st Apr 202210:10 amRNSCompliance with Market Abuse Regulation
31st Mar 202211:12 amPRNNet Asset Value(s)
31st Mar 20227:00 amRNSKepler Trust Intelligence: New Research
30th Mar 202211:10 amPRNNet Asset Value(s)
29th Mar 20225:41 pmRNSTransaction in Own Shares
29th Mar 202211:57 amPRNNet Asset Value(s)
28th Mar 20225:36 pmRNSTransaction in Own Shares
28th Mar 202212:05 pmPRNNet Asset Value(s)
25th Mar 20225:17 pmRNSTransaction in Own Shares
25th Mar 202210:37 amPRNNet Asset Value(s)
24th Mar 202210:43 amPRNNet Asset Value(s)
23rd Mar 20225:05 pmRNSTransaction in Own Shares
23rd Mar 202212:07 pmPRNNet Asset Value(s)
22nd Mar 20225:09 pmRNSTransaction in Own Shares
22nd Mar 20224:30 pmRNSDirector/PDMR Shareholding
22nd Mar 202211:35 amPRNNet Asset Value(s)
21st Mar 20226:11 pmRNSTransaction in Own Shares
21st Mar 202211:25 amPRNNet Asset Value(s)
18th Mar 20225:27 pmRNSTransaction in Own Shares
18th Mar 202211:43 amPRNNet Asset Value(s)
17th Mar 202211:14 amPRNNet Asset Value(s)
17th Mar 20227:00 amRNSPortfolio Update
16th Mar 202211:13 amPRNNet Asset Value(s)
15th Mar 202211:15 amPRNNet Asset Value(s)
14th Mar 202211:47 amPRNNet Asset Value(s)
11th Mar 202211:47 amPRNNet Asset Value(s)
10th Mar 202212:02 pmPRNNet Asset Value(s)
9th Mar 202211:22 amPRNNet Asset Value(s)
8th Mar 20226:01 pmRNSTransaction in Own Shares
8th Mar 202211:08 amPRNNet Asset Value(s)
7th Mar 20226:09 pmRNSTransaction in Own Shares
7th Mar 202211:06 amPRNNet Asset Value(s)
4th Mar 202211:33 amPRNNet Asset Value(s)
3rd Mar 202212:14 pmPRNNet Asset Value(s)
2nd Mar 202212:46 pmPRNNet Asset Value(s)
1st Mar 202211:57 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.